Granite Point Capital
VC Fund
Boston, United States
Granite Point Capital is a hedge fund. They have closed-end investment office in Boston, MA.Jeffrey Barnett, the chief operating officer of Granite Point Capital in Boston, is responsible for all aspects of the firm's business, including human resources, systems, trading, compliance and risk management. He also serves on the firm'sinvestment committee, and has been instrumental in crafting a number of its investments in private equity transactions. Launched in February of 2004, Granite Point Capital is a research-driven, long/short equity hedge fund with a global mandate and a focus on mid-small cap US equities. Although primarily focused on the public markets, it has invested in a number of PIPEs, private equity and venture-backed companies.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Granite Point Capital invests in
Stages Granite Point Capital invests in
Countries Granite Point Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jeff Barnett
|
|||
|
Scott Bushley
|
|||
Warren Lammert
|
|||
Investment Focus
Industry
- Biotechnology 3 (27%)
- Internet 2 (18%)
- Health Care 2 (18%)
- Therapeutics 2 (18%)
- News 1 (9%)
Stage
- Series B 3 (27%)
- Series A 2 (18%)
- Series C 2 (18%)
- Venture - Series Unknown 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jeff Barnett
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
|
Scott Bushley
Partner, Finances & Operations
|
Partner, Finances & Operations | Total investments: 0 | Find email | |
|
Warren Lammert
Founder & CIO
|
Founder & CIO | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cerebral Therapeutics
|
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $40M / Series C / Jun 28, 2022 | |
|
Cerebral Therapeutics
|
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $40M / Series C / Jun 28, 2022 | |
Receptor Life Sciences
|
Receptor Life Sciences is a biotechnology company | $9.7M / Series A / Apr 07, 2022 | |
Antios Therapeutics
|
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $75M / Series B / Nov 03, 2021 | |
Teikametrics
|
Teikametrics is an internet company that features an eCommerce optimization platform designed for retailers on online marketplaces. Its software platform specializes in pricing optimization, operations, and inventory for sellers of all sizes. The company was founded in 2015 and is headquartered in Boston, Massachusetts. | $40M / Series B / Jul 15, 2021 | |
|
Antios Therapeutics
|
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $96M / Series B / Apr 12, 2021 | |
|
Teikametrics
|
Teikametrics is an internet company that features an eCommerce optimization platform designed for retailers on online marketplaces. Its software platform specializes in pricing optimization, operations, and inventory for sellers of all sizes. The company was founded in 2015 and is headquartered in Boston, Massachusetts. | $15M / Venture - Series Unknown / Feb 20, 2020 | |
|
Cerebral Therapeutics
|
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $35M / Series B / Jan 06, 2020 | |
|
Cerebral Therapeutics
|
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $7.8M / Series A / Mar 08, 2019 | |
|
Cerebral Therapeutics
|
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $3M / Series A / Jun 20, 2018 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Granite Point Capital invest in?
Granite Point Capital invests primarily in Biotechnology, Internet and Health Care startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Granite Point Capital?
Public channels for Granite Point Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Granite Point Capital?
The team at Granite Point Capital includes Jeff Barnett (Chief Operating Officer), Scott Bushley (Partner, Finances & Operations) and Warren Lammert (Founder & CIO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
